Stock Data
$12.04 (2.49%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Vertex Pharmaceuticals Inc is a pioneering biotechnology firm focused on creating innovative treatments for cystic fibrosis (CF) and other serious diseases. It offers a range of CF therapies, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting different age groups and genetic mutations. Beyond CF, Vertex is exploring treatments for pain, sickle cell disease, beta thalassemia, and Type 1 Diabetes through advanced clinical trials. Founded in 1989 and based in Boston, Massachusetts, Vertex collaborates with leading biotech entities to expand its therapeutic portfolio, aiming to address unmet medical needs.
Vertex lifted full-year revenue guidance to $13.1 billion to $13.2 billion, with management now committing to at least $500 million from non-CF products this year. That guidance excludes the pending $10 billion Crinetics deal, so the next update comes after the deal closes in Q3.
Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.
The $119.5 billion cystic fibrosis franchise is being deliberately de-risked: management now counts rare endocrine disease as a fifth revenue pillar once Crinetics closes, alongside sickle cell, beta thalassemia and acute pain. For anyone still valuing Vertex as a single-disease company, the pillar count is the number to track.
Vertex's $85.00 per share all-cash deal, expected to close this quarter, now looks locked in as PALSONIFY's net product revenue more than doubled to $24.0 million. Guidance is withdrawn and there is no earnings call, so the merger vote is the only catalyst left.
Vertex reports after the close with cystic fibrosis cash flows holding steady and suzetrigine, its non-opioid pain shot, facing the street's biggest test yet on whether the pipeline can drive growth beyond CF dominance.
257 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
